TELO - NASDAQ
Telomir Pharmaceuticals, Inc. Common Stock
$1.48
+0.0000%Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
At a Glance
Live SnapshotNo Investing Cash Flow Data
TELO has not reported any investing cash flow values in the available annual periods.
Telomir Pharmaceuticals, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Telomir Pharmaceuticals, Inc. Common Stock Cash Flow Statement
TELO • NASDAQ
| Telomir Pharmaceuticals, Inc. Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-10.4M | -16.5M | -13.1M | -854.1K | -138.1K | |
0.0 | 4.3M | 0.0 | 0.0 | 0.0 | |
5.3M | 6.9M | 0.0 | 0.0 | 0.0 | |
840K | 130K | 9.1M | 0.0 | 0.0 | |
594.7K | 126.5K | 113.8K | 385.5K | 18.7K | |
-3.7M | -5.1M | -3.9M | -468.7K | -119.4K | |
INVESTING ACTIVITIES | |||||
FINANCING ACTIVITIES | |||||
9.6M | 6.8M | 1M | 0.0 | 0.0 | |
0.0 | -101K | 3.2M | 462.4K | 0.0 | |
155.5K | -396.6K | -310.4K | 7.7K | 119.4K | |
9.7M | 6.3M | 3.9M | 470.1K | 119.4K | |
CASH FLOW SUMMARY | |||||
6M | 1.3M | -188.0 | 1.4K | 0.0 | |
1.3M | 1.2K | 1.4K | 0.0 | 0.0 | |
7.3M | 1.3M | 1.2K | 1.4K | 0.0 | |
-3.7M | -5.1M | -3.9M | -468.7K | -119.4K |
SEC Filings
TELO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 31, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 22, 2025 | December 17, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 17, 2025 | 2025 |
Related Guides
Continue your TELO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.